ArticleFrontiers in endocrinology2025
Independent and combined associations of high-density lipoprotein cholesterol-modified triglyceride-glucose index with all-cause and cardiovascular mortality in patients with acute decompensated heart failure.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Head-to-head comparison of stress hyperglycemia ratio versus triglyceride-glucose index for predicting mortality in heart failure: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Inflammatory storm and metabolic disorders: unraveling heterogeneity in mortality risk for comorbid diabetes mellitus and heart failure via the C-reactive protein-triglyceride-glucose index.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dysregulation of glucolipid metabolism is a central pathological mechanism underlying acute decompensated heart failure (ADHF) and significantly impacts its poor prognosis. This study aims to investigate the association between the high-density lipoprotein cholesterol-modified triglyceride-glucose index (defined as TyG/HDL-C) and their interaction with 30-day mortality in patients with ADHF. Methods: From 2018 to 2024, 2,329 ADHF patients enrolled in the Jiangxi-ADHF II cohort were included. Multivariable Cox regression models were utilized to evaluate the association between TyG/HDL-C ratio and 30-day all-cause/cardiovascular mortality risk. A 3-dimensional interaction model was employed to examine the dose-response relationships of TyG and HDL-C with mortality risk. Additionally, exploratory mediation models were constructed to investigate potential mediating effects of inflammation, oxidative stress, and nutritional metabolism in the association between TyG/HDL-C ratio and mortality risk. Results: At 30-day follow-up, 150 deaths occurred, 115 of which were cardiovascular. Multivariable Cox regression showed that each standard deviation increase in TyG/HDL-C ratio increased 30-day all-cause mortality by 24% and cardiovascular mortality by 20%. These findings demonstrated robustness across sensitivity analyses conducted from four dimensions: model adjustment, causal timing, population heterogeneity, and data integrity. Notably, the subsequent 3-dimensional interaction model analysis revealed a complex U-shaped association - resembling a concave surface of a radio telescope - between the combined effects of TyG index and HDL-C on mortality risk. Specifically, both excessively low and high combinations of TyG index and HDL-C were associated with elevated 30-day mortality risk in ADHF patients, while the lowest mortality risk interval occurred when the TyG index remained within 7.5-9.0 and HDL-C levels were maintained at 1.0-1.5 mmol/L. Mediation analysis further suggested that inflammatory and nutritional pathways might serve as significant mediators of mortality risk related to TyG/HDL-C ratio. Discussion: The TyG/HDL-C ratio emerged as an independent predictor of short-term all-cause and cardiovascular mortality in ADHF patients, demonstrating significant enhancement in predictive performance for these outcomes. Most notably, the concave-shaped interaction pattern revealed by 3-dimensional interaction analysis provided an evidence-based threshold framework for metabolic management in ADHF patients, which may hold substantial clinical significance for reducing future mortality risks in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.